Emanuele Gabellieri, PhD

Emanuele Gabellieri earned a PhD in pharmaceutical chemistry from the University of Siena. Dr. Gabellieri is the Head of Medicinal Chemistry at Booster since 2020, where he leads the small molecules pipeline development. He began his career in 2007 at Siena Biotech, where he helped identify an inhibitor for BACE-1, which entered Phase 1 in 2012. After a year as an organic process chemist, he joined AC Immune in 2013, working on diagnostic projects like Tau PET diagnostics, including the discovery of [18F]PI-2620, now in Phase 3. In 2024, PI-2620 received FDA Fast Track designation for Alzheimer’s and neurodegenerative diseases. He led the discovery of ACI-3024, a Tau aggregation inhibitor for Alzheimer's, entering Phase 1 in 2019, and resulted in a CHF 80M deal with Eli Lilly. In 2019, he became Project Leader of a multidisciplinary team focused on discovering new compounds to treat neuroinflammatory diseases by inhibiting NLRP3.